Drugs clopidogrel and modified-release dipyridamole are both recommended for the prevention of occlusive vascular events under the guidance, which is open for comment until 25 August.
NICE has recommended clopidogrel as a treatment option for patients who have had an ischaemic stroke, who have peripheral arterial disease (PAD) or who have multivascular disease.
Meanwhile, modified-release dipyridamole plus aspirin is recommended as an option for patients who have had a TIA. For people who have had an ischaemic stroke, modified-release dipyridamole plus aspirin should only be used where clopidogrel is contraindicated or not tolerated.
NICE also recommends modified-release dipyridamole alone as an option for people who have had an ischaemic stroke only where treatment with aspirin and clopidogrel is contraindicated or not tolerated.
The draft guidance will replace the original recommendations published in 2005.
Take part in our new White Paper 2010 survey to be entered into a draw for £50 worth of Amazon vouchers.